Medeon Biodesign (6499) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Medeon Biodesign (6499) has a cash flow conversion efficiency ratio of -0.118x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-133.97 Million ≈ $-4.22 Million USD) by net assets (NT$1.13 Billion ≈ $35.68 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Medeon Biodesign balance sheet quality to measure how much of total assets are equity-financed.
Medeon Biodesign - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Medeon Biodesign's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 6499 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Medeon Biodesign Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Medeon Biodesign ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BLE KEDROS REIC EO 1
F:N67
|
N/A |
|
Syscom Computer Engineering Co
TW:2453
|
0.039x |
|
Omiris AG
F:HBD1
|
N/A |
|
CTT Systems AB
ST:CTT
|
-0.034x |
|
Aimia Inc
TO:AIM
|
0.110x |
|
AROBS TRANSILVANIA SOFTWARE SA
RO:AROBS
|
0.032x |
|
Topco Technologies
TWO:3388
|
0.039x |
|
SAMG Entertainment Co. Ltd.
KQ:419530
|
-0.006x |
Annual Cash Flow Conversion Efficiency for Medeon Biodesign (2017–2024)
The table below shows the annual cash flow conversion efficiency of Medeon Biodesign from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Medeon Biodesign.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$1.54 Billion ≈ $48.39 Million |
NT$-832.66 Million ≈ $-26.23 Million |
-0.542x | -70.27% |
| 2023-12-31 | NT$2.37 Billion ≈ $74.72 Million |
NT$-755.08 Million ≈ $-23.79 Million |
-0.318x | -152.84% |
| 2022-12-31 | NT$3.66 Billion ≈ $115.42 Million |
NT$-461.34 Million ≈ $-14.53 Million |
-0.126x | -79.78% |
| 2021-12-31 | NT$4.19 Billion ≈ $131.96 Million |
NT$-293.38 Million ≈ $-9.24 Million |
-0.070x | -22.59% |
| 2020-12-31 | NT$2.65 Billion ≈ $83.41 Million |
NT$-151.27 Million ≈ $-4.77 Million |
-0.057x | +46.90% |
| 2019-12-31 | NT$2.25 Billion ≈ $70.85 Million |
NT$-241.99 Million ≈ $-7.62 Million |
-0.108x | -160.10% |
| 2018-12-31 | NT$1.80 Billion ≈ $56.66 Million |
NT$322.05 Million ≈ $10.15 Million |
0.179x | +188.32% |
| 2017-12-31 | NT$1.53 Billion ≈ $48.29 Million |
NT$-310.76 Million ≈ $-9.79 Million |
-0.203x | -- |
About Medeon Biodesign
Medeon Biodesign, Inc. engages in the research and development, manufacturing, and sale of medical devices in the United States. The company focuses on developing devices for minimally invasive surgeries, such as Cross-Seal, a large bore vascular closure system; Urocross, an expander system for treating lower urinary tract symptoms associated with benign prostatic hyperplasia; Duett, a vascular g… Read more